Literature DB >> 25746966

Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults.

James Fingleton1, Justin Travers2, Mathew Williams3, Thomas Charles3, Darren Bowles4, Rianne Strik3, Philippa Shirtcliffe4, Mark Weatherall5, Richard Beasley6.   

Abstract

BACKGROUND: Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment.
OBJECTIVE: The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy.
METHODS: We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes.
RESULTS: Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group.
CONCLUSION: Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Phenotype; asthma; bronchodilator; chronic obstructive pulmonary disease; inhaled corticosteroid

Mesh:

Substances:

Year:  2015        PMID: 25746966     DOI: 10.1016/j.jaci.2015.01.013

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

Review 1.  Role of Obesity in Asthma: Mechanisms and Management Strategies.

Authors:  Hayley A Scott; Lisa G Wood; Peter G Gibson
Journal:  Curr Allergy Asthma Rep       Date:  2017-08       Impact factor: 4.806

2.  American Thoracic Society/National Heart, Lung, and Blood Institute Asthma-Chronic Obstructive Pulmonary Disease Overlap Workshop Report.

Authors:  Prescott G Woodruff; Maarten van den Berge; Richard C Boucher; Christopher Brightling; Esteban G Burchard; Stephanie A Christenson; MeiLan K Han; Michael J Holtzman; Monica Kraft; David A Lynch; Fernando D Martinez; Helen K Reddel; Don D Sin; George R Washko; Sally E Wenzel; Antonello Punturieri; Michelle M Freemer; Robert A Wise
Journal:  Am J Respir Crit Care Med       Date:  2017-08-01       Impact factor: 21.405

Review 3.  Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence.

Authors:  Kristin L Hines; R Stokes Peebles
Journal:  Curr Allergy Asthma Rep       Date:  2017-03       Impact factor: 4.806

4.  Gender and asthma-chronic obstructive pulmonary disease overlap syndrome.

Authors:  Anne G Wheaton; Roy A Pleasants; Janet B Croft; Jill A Ohar; Khosrow Heidari; David M Mannino; Yong Liu; Charlie Strange
Journal:  J Asthma       Date:  2016-04-06       Impact factor: 2.515

5.  What pulmonologists think about the asthma-COPD overlap syndrome.

Authors:  Marc Miravitlles; Bernardino Alcázar; Francisco Javier Alvarez; Teresa Bazús; Myriam Calle; Ciro Casanova; Carolina Cisneros; Juan P de-Torres; Luis M Entrenas; Cristóbal Esteban; Patricia García-Sidro; Borja G Cosio; Arturo Huerta; Milagros Iriberri; José Luis Izquierdo; Antolín López-Viña; José Luis López-Campos; Eva Martínez-Moragón; Luis Pérez de Llano; Miguel Perpiñá; José Antonio Ros; José Serrano; Juan José Soler-Cataluña; Alfons Torrego; Isabel Urrutia; Vicente Plaza
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-15

6.  Serum periostin in obstructive airways disease.

Authors:  James Fingleton; Irene Braithwaite; Justin Travers; Darren Bowles; Rianne Strik; Rob Siebers; Cecile Holweg; John Matthews; Mark Weatherall; Richard Beasley
Journal:  Eur Respir J       Date:  2016-02-25       Impact factor: 16.671

7.  Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1.

Authors:  Timothy S C Hinks; Tom Brown; Laurie C K Lau; Hitasha Rupani; Clair Barber; Scott Elliott; Jon A Ward; Junya Ono; Shoichiro Ohta; Kenji Izuhara; Ratko Djukanović; Ramesh J Kurukulaaratchy; Anoop Chauhan; Peter H Howarth
Journal:  J Allergy Clin Immunol       Date:  2016-02-03       Impact factor: 10.793

8.  Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD.

Authors:  Shih-Lung Cheng; Hsu Hui Wang; Ching-Hsiung Lin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-07-31

9.  Clinical and inflammatory characteristics of Asthma-COPD overlap in workers with occupational asthma.

Authors:  Iñigo Ojanguren; Gregory Moullec; Jad Hobeika; Marc Miravitlles; Catherine Lemiere
Journal:  PLoS One       Date:  2018-03-02       Impact factor: 3.240

Review 10.  Therapeutic interventions in severe asthma.

Authors:  Giorgio Walter Canonica; Gianenrico Senna; Patrick D Mitchell; Paul M O'Byrne; Giovanni Passalacqua; Gilda Varricchi
Journal:  World Allergy Organ J       Date:  2016-11-28       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.